Overview

Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-28
Target enrollment:
Participant gender:
Summary
If this study has a cardio protective effect it will affect the mortality and morbidity of advanced CKD patients and improve their quality of life
Phase:
PHASE3
Details
Lead Sponsor:
Al-Azhar University
Treatments:
dapagliflozin